Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review

Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review

Spinocerebellar ataxia (SCA) is part of the cerebellar neurodegenerative illness group that’s numerous in genetics and phenotypes. It often exhibits autosomal dominant inheritance. SCAs, at all times along with the cerebellar degeneration, could exhibit scientific deficits in brainstem or eye, particularly retina or optic nerve. Apparently, autosomal dominant SCAs share a typical genetic mechanism; the size of the glutamine chain is abnormally expanded because of the improve within the cytosine-adenine-guanine (CAG) repeats of the illness inflicting gene. Research have urged that the mutant ataxin induces alteration of protein conformation and irregular aggregation leading to nuclear inclusions, and causes mobile lack of photoreceptors by way of a poisonous impact.

In consequence, these pathologic modifications induce a downregulation of genes concerned within the phototransduction, growth, and differentiation of photoreceptors resembling CRX, one of many photoreceptor transcription components. Nonetheless, the precise mechanism of neuronal degeneration by mutant ataxin restricted to solely sure sort of neuronal cell together with cerebellar Purkinje neurons and photoreceptor continues to be unclear. The commonest SCAs are varieties 1, 2, 3, 6, 7, and 17 which comprise about 80% of autosomal dominant SCA instances. Numerous elements of eye motion abnormalities are evident relying on the diploma of cerebellar and brainstem degeneration in SCAs. As well as, sure varieties of SCAs resembling SCA7 are characterised by each cerebellar ataxia and visible loss primarily because of retinal degeneration.

The severity of the retinopathy can fluctuate from occult macular photoreceptor disruption to in depth retinal atrophy and is correlated with the variety of CAG repeats. The worth of utilizing optical coherence tomography along side electrodiagnostic and genetic testing is emphasised as the mix of those exams can present vital data concerning the etiology, morphological analysis, and purposeful significances. Due to this fact, ophthalmologists want to acknowledge and differentiate SCAs to be able to correctly diagnose and consider the illness. On this assessment, we’ve described and mentioned SCAs displaying ophthalmic abnormalities with explicit consideration to their ophthalmic options, neurodegenerative mechanisms, genetics, and future views.

The blood-brain barrier is disrupted in Machado-Joseph illness/spinocerebellar ataxia sort 3: proof from transgenic mice and human autopsy samples

Blood-brain barrier (BBB) disruption is a typical characteristic in neurodegenerative ailments. Nonetheless, BBB integrity has not been assessed in spinocerebellar ataxias resembling Machado-Joseph illness/SCA sort 3, a genetic dysfunction, triggered by polyglutamine-expanded ataxin-3. To analyze that, BBB integrity was evaluated in a transgenic mouse mannequin of MJD and in human autopsy mind tissues.Firstly, we investigated the BBB permeability in MJD mice by: i) assessing the extravasation of the Evans blue (EB) dye and blood-borne proteins (e.g fibrinogen) within the cerebellum by immunofluorescence, and ii) in vivo Dynamic Distinction Enhanced-Magnetic Resonance Imaging.
The presence of ataxin-Three aggregates in mind blood vessels and the degrees of tight junction (TJ)-associated proteins had been additionally explored by immunofluorescence and western blotting. Human mind samples had been used to verify BBB permeability by evaluating fibrinogen extravasation, co-localization of ataxin-Three aggregates with mind blood vessels and neuroinflammation.Within the cerebellum of the mouse mannequin of MJD, there was a 5-fold improve in EB accumulation when in comparison with age-matched controls. Furthermore, vascular permeability displayed a 13-fold improve demonstrated by DCE-MRI. These outcomes had been validated by the 2-fold improve in fibrinogen extravasation in transgenic animals evaluating to controls.
Apparently, mutant ataxin-Three aggregates had been detected in cerebellar blood vessels of transgenic mice, accompanied by alterations of TJ-associated proteins in cerebellar endothelial cells, particularly a 29% lower in claudin-5 oligomers and a 10-fold improve in an occludin cleavage fragment. These outcomes had been validated in autopsy mind samples from MJD sufferers as we detected fibrinogen extravasation throughout BBB, the presence of ataxin-Three aggregates in blood vessels and related microgliosis.Altogether, our outcomes show BBB impairment in MJD/SCA3. These findings contribute for a greater understanding of the illness mechanisms and opens the chance to deal with MJD with medicinal merchandise that in regular situations wouldn’t cross the BBB.
 Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review

Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review

Hypocretin/orexin loss modifications the hypothalamic immune response.

Hypocretin, also called orexin, maintains the vigilance state and regulates varied physiological processes, resembling arousal, sleep, meals consumption, vitality expenditure, and reward. Beforehand, we discovered that when wild-type mice and hypocretin/ataxin-Three littermates (that are depleted of hypothalamic hypocretin-expressing neurons postnatally) had been administered lipopolysaccharide (LPS), the 2 genotypes exhibited important variations of their sleep/wake cycle, together with variations within the diploma of improve in sleep durations and in restoration from illness behaviour.
Within the current examine, we examined modifications within the hypothalamic vigilance system and within the hypothalamic expression of inflammatory components in response to LPS in hypocretin/ataxin-Three mice. Peripheral immune problem with LPS affected the hypothalamic immune response and vigilance states. This response was altered by the lack of hypocretin. Hypocretin expression was inhibited after LPS injection in each hypocretin/ataxin-Three mice and their wild-type littermates, however expression was utterly abolished solely in hypocretin/ataxin-Three mice.

Ataxin 1 Antibody

AF6347-200ul 200ul
EUR 350

Ataxin 1 Antibody

ABF6347 100ug
EUR 325

Ataxin 1 Antibody

MBS801582-01mg 0.1mg
EUR 435

Ataxin 1 Antibody

MBS801582-5x01mg 5x0.1mg
EUR 1700

Ataxin 1 Antibody

MBS804474-01mg 0.1mg
EUR 435

Ataxin 1 Antibody

MBS804474-5x01mg 5x0.1mg
EUR 1700

Ataxin 1 Antibody

MBS8509598-01mg 0.1mg
EUR 305

Ataxin 1 Antibody

MBS8509598-01mLAF405L 0.1mL(AF405L)
EUR 465

Ataxin 1 Antibody

MBS8509598-01mLAF405S 0.1mL(AF405S)
EUR 465

Ataxin 1 Antibody

MBS8509598-01mLAF610 0.1mL(AF610)
EUR 465

Ataxin 1 Antibody

MBS8509598-01mLAF635 0.1mL(AF635)
EUR 465

Ataxin 1 Antibody

MBS8512374-005mg 0.05mg
EUR 235

Ataxin 1 Antibody

MBS8512374-01mg 0.1mg
EUR 305

Ataxin 1 Antibody

MBS8512374-01mLAF405M 0.1mL(AF405M)
EUR 465

Ataxin 1 Antibody

MBS8512374-01mLAF546 0.1mL(AF546)
EUR 465

Ataxin 1 Antibody

MBS8512374-01mLAF750 0.1mL(AF750)
EUR 465

Ataxin 1 Antibody

MBS9601916-01mL 0.1mL
EUR 260

Ataxin 1 Antibody

MBS9601916-02mL 0.2mL
EUR 305

Ataxin 1 Antibody

MBS9601916-5x02mL 5x0.2mL
EUR 1220

Ataxin 1 Antibody

MBS9503754-005mL 0.05mL
EUR 285

Ataxin 1 Antibody

MBS9503754-01mL 0.1mL
EUR 385

Ataxin 1 Antibody

MBS9503754-5x01mL 5x0.1mL
EUR 1590

Ataxin-1 Antibody

E90506 100μg
EUR 255
Description: Available in various conjugation types.

Ataxin-1 Antibody

MBS8503880-01mg 0.1mg
EUR 325

Ataxin-1 Antibody

MBS8503880-01mLAF405L 0.1mL(AF405L)
EUR 565

Ataxin-1 Antibody

MBS8503880-01mLAF405S 0.1mL(AF405S)
EUR 565

Ataxin-1 Antibody

MBS8503880-01mLAF610 0.1mL(AF610)
EUR 565

Ataxin-1 Antibody

MBS8503880-01mLAF635 0.1mL(AF635)
EUR 565

Ataxin-1 Antibody

B0771-100ul 100μl
EUR 217
Description: Ataxin-1 Rabbit Polyclonal Antibody

Ataxin-1 Antibody

B0771-50ul 50μl
EUR 143.5
Description: Ataxin-1 Rabbit Polyclonal Antibody

Ataxin 1 Antibody: HRP

MBS801879-01mg 0.1mg
EUR 475

Ataxin 1 Antibody: HRP

MBS801879-5x01mg 5x0.1mg
EUR 1885

Ataxin 1 Antibody: RPE

MBS802293-01mg 0.1mg
EUR 485

Ataxin 1 Antibody: RPE

MBS802293-5x01mg 5x0.1mg
EUR 1925

Ataxin 1 Antibody: RPE

MBS802630-01mg 0.1mg
EUR 485

Ataxin 1 Antibody: RPE

MBS802630-5x01mg 5x0.1mg
EUR 1925

Ataxin 1 Antibody: HRP

MBS803533-01mg 0.1mg
EUR 475

Ataxin 1 Antibody: HRP

MBS803533-5x01mg 5x0.1mg
EUR 1885

Ataxin 1 Antibody: FITC

MBS801486-01mg 0.1mg
EUR 480

Ataxin 1 Antibody: FITC

MBS801486-5x01mg 5x0.1mg
EUR 1905

Ataxin 1 Antibody: FITC

MBS804612-01mg 0.1mg
EUR 480

Ataxin 1 Antibody: FITC

MBS804612-5x01mg 5x0.1mg
EUR 1905

Ataxin 1 Antibody / ATXN1

R32138 100 ug
EUR 356.15
Description: Ataxin-1 is a protein that in humans is encoded by the ATXN1 gene. The ATXN1 gene had been mapped to 6p23 by in situ hybridization. Ataxin-1 (ATXN1), a causative factor for spinocerebellar ataxia type 1 (SCA1), and the related Brother of ATXN1 (BOAT1) are human proteins involved in transcriptional repression. ATXN1 and BOAT1 might participate in several Notch-controlled developmental and pathological processes.

Ataxin 1 Antibody: PerCP

MBS800951-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: PerCP

MBS800951-5x01mg 5x0.1mg
EUR 1935

Ataxin 1 Antibody: PerCP

MBS803830-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: PerCP

MBS803830-5x01mg 5x0.1mg
EUR 1935

Ataxin 1 Antibody / ATXN1

RQ7132 100ug
EUR 300.3
Description: Ataxin-1 is a protein that in humans is encoded by the ATXN1 gene. It is a causative factor for spinocerebellar ataxia type 1 (SCA1), and the related Brother of ATXN1 (BOAT1), are human proteins involved in transcriptional repression. ATXN1 and BOAT1 might participate in several Notch-controlled developmental and pathological processes.

Ataxin 1 Antibody: Biotin

MBS802698-01mg 0.1mg
EUR 485

Ataxin 1 Antibody: Biotin

MBS802698-5x01mg 5x0.1mg
EUR 1920

Ataxin 1 Antibody: Biotin

MBS804344-01mg 0.1mg
EUR 485

Ataxin 1 Antibody: Biotin

MBS804344-5x01mg 5x0.1mg
EUR 1920

Ataxin 1 Antibody: ATTO 488

MBS800855-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 488

MBS800855-5x01mg 5x0.1mg
EUR 1940

Ataxin 1 Antibody: ATTO 488

MBS802787-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 488

MBS802787-5x01mg 5x0.1mg
EUR 1940

Ataxin 1 Antibody: ATTO 390

MBS803174-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 390

MBS803174-5x01mg 5x0.1mg
EUR 1945

Ataxin 1 Antibody: ATTO 390

MBS803372-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 390

MBS803372-5x01mg 5x0.1mg
EUR 1945

Ataxin 1 Antibody: ATTO 594

MBS804824-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 594

MBS804824-5x01mg 5x0.1mg
EUR 1940

Ataxin 1 Antibody: ATTO 594

MBS804868-01mg 0.1mg
EUR 490

Ataxin 1 Antibody: ATTO 594

MBS804868-5x01mg 5x0.1mg
EUR 1940

Ataxin-1 Polyclonal Antibody

ABP50719-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Polyclonal Antibody

ABP50719-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Polyclonal Antibody

ABP50719-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Polyclonal Antibody

40621-100ul 100ul
EUR 302.4

Ataxin-1 Polyclonal Antibody

40621-50ul 50ul
EUR 224.4

Ataxin-1 Polyclonal Antibody

E040621 100μg/100μl
EUR 255
Description: Available in various conjugation types.

Ataxin-1 Polyclonal Antibody

E20-70373 100ug
EUR 225
Description: Available in various conjugation types.

Ataxin-1 Monoclonal Antibody

BT-MCA0188-100ul 100ul Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted

Ataxin-1 Monoclonal Antibody

BT-MCA0188-50ul 50ul Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted

Ataxin-1 Polyclonal Antibody

E44H01617 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Ataxin-1 Polyclonal Antibody

BT-AP00685-100ul 100ul Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 Polyclonal Antibody

BT-AP00685-20ul 20ul Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 Polyclonal Antibody

BT-AP00685-50ul 50ul Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 Polyclonal Antibody

MBS9404076-005mL 0.05mL
EUR 245

Ataxin-1 Polyclonal Antibody

MBS9404076-01mL 0.1mL
EUR 305

Ataxin-1 Polyclonal Antibody

MBS9404076-5x01mL 5x0.1mL
EUR 1230

Ataxin-1 Polyclonal Antibody

MBS8521354-01mg 0.1mg
EUR 305

Ataxin-1 Polyclonal Antibody

MBS8521354-01mLAF405L 0.1mL(AF405L)
EUR 465

Ataxin-1 Polyclonal Antibody

MBS8521354-01mLAF405S 0.1mL(AF405S)
EUR 465

Ataxin-1 Polyclonal Antibody

MBS8521354-01mLAF610 0.1mL(AF610)
EUR 465

Ataxin-1 Polyclonal Antibody

MBS8521354-01mLAF635 0.1mL(AF635)
EUR 465

Ataxin-1 Monoclonal Antibody

MBS191333-01mg 0.1mg
EUR 650

Ataxin-1 Monoclonal Antibody

MBS191333-5x01mg 5x0.1mg
EUR 2925

Ataxin-1 Monoclonal Antibody

MBS191334-01mg 0.1mg
EUR 650

Ataxin-1 Monoclonal Antibody

MBS191334-5x01mg 5x0.1mg
EUR 2925

Ataxin-1 Polyclonal Antibody

MBS2537932-002mL 0.02mL
EUR 140

Ataxin-1 Polyclonal Antibody

MBS2537932-006mL 0.06mL
EUR 180

Ataxin-1 Polyclonal Antibody

MBS2537932-012mL 0.12mL
EUR 260

Ataxin-1 Polyclonal Antibody

MBS2537932-02mL 0.2mL
EUR 405

Ataxin 1 (ATXN1) Antibody

20-abx100304
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ataxin 1 (ATXN1) Antibody

20-abx129635
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ataxin 1 (pS775) Antibody

20-abx121842
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

Ataxin 1 (ATXN1) Antibody

20-abx126836
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul

Ataxin 1 (ATXN1) Antibody

abx145346-100ug 100 ug
EUR 469.2

Ataxin 1 (ATXN1) Antibody

20-abx133167
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

Ataxin 1 (ATXN1) Antibody

abx031721-400ul 400 ul
EUR 627.6

Ataxin 1 (ATXN1) Antibody

abx031721-80l 80 µl
EUR 343.2

Ataxin 1 (ATXN1) Antibody

20-abx004749
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Ataxin 1 (pS776) Antibody

abx010423-100ug 100 ug
EUR 526.8

Ataxin 1 (ATXN1) Antibody

abx010425-100ul 100 ul
EUR 493.2

Ataxin 1 (ATXN1) Antibody

20-abx242069
  • Ask for price
  • Ask for price
  • 100 ul
  • 50 ul

Ataxin 1 (ATXN1) Antibody

20-abx214569
  • Ask for price
  • Ask for price
  • 100 ul
  • 50 ul

Ataxin 1 (ATXN1) Antibody

20-abx171342
  • Ask for price
  • Ask for price
  • 1 mg
  • 200 ug

Ataxin 1 (ATXN1) Antibody

20-abx325351
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

Ataxin 1 (ATXN1) Antibody

abx431572-200ul 200 ul
EUR 343.2

Ataxin 1 (ATXN1) Antibody

abx432383-200ul 200 ul
EUR 343.2

Ataxin 1 (ATXN1) Antibody

abx445066-100ug 100 ug
EUR 627.6

Ataxin 1 (ATXN1) Antibody

abx445084-100ug 100 ug
EUR 627.6

Ataxin 1 (ATXN1) Antibody

20-abx320078
  • Ask for price
  • Ask for price
  • 100 ul
  • 50 ul

Ataxin 1 (pS775) Antibody

E38PA4341 100ul
EUR 225
Description: Available in various conjugation types.

Ataxin 1 (ATXN1) Antibody

abx129635-100l 100 µl
EUR 262.5

Ataxin 1 (ATXN1) Antibody

abx129635-1ml 1 ml
EUR 687.5

Ataxin 1 (ATXN1) Antibody

abx129635-200l 200 µl
EUR 325

Ataxin 1 (ATXN1) Antibody

abx171342-1ml 1 ml
EUR 712.5

Ataxin 1 (ATXN1) Antibody

abx031721-400l 400 µl
EUR 518.75

Ataxin 1 (ATXN1) Antibody

abx242069-96tests 96 tests
EUR 250

Ataxin 1 (ATXN1) Antibody

abx145346-1096tests 10 × 96 tests Ask for price

Ataxin 1 (ATXN1) Antibody

abx145346-596tests 5 × 96 tests Ask for price

Ataxin 1 (ATXN1) Antibody

abx145346-96tests 96 tests
EUR 337.5

Ataxin 1 (ATXN1) Antibody

abx214569-100tests 100 tests
EUR 350

Ataxin 1 (ATXN1) Antibody

abx214569-200tests 200 tests Ask for price

Ataxin 1 (ATXN1) Antibody

abx214569-20tests 20 tests
EUR 250

Ataxin 1 (ATXN1) Antibody

abx325351-100g 100 µg
EUR 250

Ataxin 1 (ATXN1) Antibody

abx325351-50g 50 µg
EUR 187.5

Ataxin 1 (ATXN1) Antibody

abx431572-200l 200 µl
EUR 250

Ataxin 1 (ATXN1) Antibody

abx432383-100g 100 µg
EUR 250

Ataxin 1 (ATXN1) Antibody

abx320078-100l 100 µl
EUR 350

Ataxin 1 (ATXN1) Antibody

abx320078-50l 50 µl
EUR 237.5

Ataxin 1 (ATXN1) Antibody

abx445066-100g 100 µg
EUR 550

Ataxin 1 (ATXN1) Antibody

abx445084-100g 100 µg
EUR 550

Ataxin 1 (ATXN1) Antibody

abx004749-100l 100 µl
EUR 400

Ataxin 1 (ATXN1) Antibody

abx004749-20l 20 µl
EUR 175

Ataxin 1 (ATXN1) Antibody

abx004749-50l 50 µl
EUR 275

Ataxin 1 (ATXN1) Antibody

abx010425-100g 100 µg Ask for price

Ataxin 1 (ATXN1) Antibody

abx010425-10g 10 µg
EUR 362.5

Ataxin 1 (ATXN1) Antibody

abx010425-200g 200 µg Ask for price

Ataxin 1 (ATXN1) Antibody

abx100304-100l 100 µl
EUR 250

Ataxin 1 (ATXN1) Antibody

abx100304-1ml 1 ml
EUR 675

Ataxin 1 (ATXN1) Antibody

abx100304-200l 200 µl
EUR 312.5

Ataxin 1 (pS775) Antibody

MBS8582451-01mL 0.1mL
EUR 305

Ataxin 1 (pS775) Antibody

MBS8582451-01mLAF405L 0.1mL(AF405L)
EUR 465

Ataxin 1 (pS775) Antibody

MBS8582451-01mLAF405S 0.1mL(AF405S)
EUR 465

Ataxin 1 (pS775) Antibody

MBS8582451-01mLAF610 0.1mL(AF610)
EUR 465

Ataxin 1 (pS775) Antibody

MBS8582451-01mLAF635 0.1mL(AF635)
EUR 465

Ataxin 3 antibody

22437 100ul
EUR 479

Ataxin 3 antibody

22437-100ul 100ul
EUR 468

Ataxin 3 Antibody

DF6375 200ul
EUR 420

Ataxin 3 Antibody

DF6375-100ul 100ul
EUR 280

Ataxin 3 Antibody

DF6375-200ul 200ul
EUR 350

Ataxin 2 Antibody

E38PA2046 100ul
EUR 225
Description: Available in various conjugation types.
Will increase within the variety of histidine decarboxylase (HDC)-positive cells and in Hdc mRNA expression had been present in hypocretin/ataxin-Three mice, and this improve was suppressed by LPS. Hypocretin loss didn’t affect the change in expression of hypothalamic inflammatory components in response to LPS, apart from interferon gamma and colony stimulating issue 3.

Leave a Reply

Your email address will not be published.